March 21, 2026
With Texas's new hemp regulations taking effect March 31, a lot of vendors and customers are asking the same question: "Smokables are done, but gummies and drinks will still be fine, right?" It's a reasonable assumption. Store owners are already planning their pivot. Some are doubling down on edibles. Others are adding beverages to fill the gap.
The short answer is: yes, gummies and drinks do survive the March 31 rules. But the story doesn't end there, and the details matter more than most people realize. Let's walk through the actual math and what it means for consumers and businesses.
Under Texas law and the 2018 Farm Bill, hemp products must contain no more than 0.3% delta-9 THC by dry weight. That's the threshold. Gummies survive not because of a special exemption — there isn't one — but because of basic chemistry.
Here's how the math works: A typical gummy weighs about 3.5 grams (3,500mg). That weight is almost entirely sugar, gelatin, corn syrup, citric acid, and flavoring — the same ingredients as any gas station gummy bear. The THC is a tiny fraction of the total weight. At 0.3% THC by dry weight, a 3.5-gram gummy can legally contain up to 10.5 milligrams of delta-9 THC. A heavier 5.5-gram gummy can hold about 15mg. A 12-ounce THC beverage? The liquid weight is so large that 5–10mg of THC registers as a tiny fraction of a percent. These products pass easily.
The new DSHS "total THC" formula (Total THC = delta-9 + 0.877 × THCA) is what kills smokable flower. A hemp flower with 25% THCA calculates out to roughly 22% total THC — wildly over the 0.3% cap. But gummies are made with already-decarboxylated delta-9 THC. They contain virtually no THCA. The new formula doesn't change their numbers.
So a 10mg gummy passes. That's actually better than a lot of people expected. For newer or lighter users, 10mg is a real dose — it's noticeable and can be genuinely helpful for sleep, stress, or mild pain.
Here's where it gets complicated. A 10mg gummy is one thing. But the gummies most experienced users actually buy are 25mg, 50mg, or higher. That's the standard at most hemp shops across Texas. If you've been using cannabis regularly, 10mg may not do much for you. A lot of people need 25–50mg to get meaningful relief.
Under the 0.3% rule, getting to 25mg in a single gummy means that gummy needs to weigh about 8.3 grams — more than double a normal gummy. At 50mg, you'd need a 16.7-gram gummy. That's basically a candy bar. It's technically possible, but it changes the product entirely. You're not eating a gummy anymore. You're eating a chunk of gelatin the size of your thumb just to hit a normal dose.
The alternative is eating two or three smaller gummies at once — which works, but costs more and means the per-serving pricing isn't what it used to be. For businesses, the margins get tighter. For consumers, the costs go up.
This is the part that gets overlooked. Not everyone can rely on edibles. And for those people, the March 31 rules create a real problem.
Edibles take 45 minutes to 90 minutes to kick in. That's just how digestion works. For someone managing chronic pain or winding down at night, the wait is fine. But for a veteran dealing with an acute PTSD episode, or someone with sudden breakthrough pain, that delay matters. Allen Kirk, managing partner at Full Spectrum in San Angelo, explained: "A smokeable item can provide instant relief, whereas gummies or oils take 45 minutes to an hour and a half to work."
Beyond timing, some people simply don't process edibles well. GI conditions can affect absorption. Certain liver enzyme variations mean some people metabolize THC too quickly to feel edibles at any dose, while others metabolize it so slowly that dosing becomes unpredictable. Diabetic consumers may not want to eat sugar-based gummies multiple times a day. These aren't edge cases — they're a significant portion of the customer base.
When smokable hemp disappears on March 31, these consumers lose their primary option. Kirk put it directly: "Customers are going to go back to the street. They're going to buy sketchy products from sketchy individuals." Heather Fazio of the Texas Cannabis Policy Center agreed: "Changing to these unreasonably restrictive testing standards would push this marketplace underground, handing it over to illicit operators."
This is a fair question. Smokable products represent 50–70% of sales at most Texas hemp shops. Losing that revenue while absorbing new licensing fees — retail went from $155 to $5,000 per year, manufacturing from $258 to $10,000 per facility — is a serious challenge. Michael Busby at The Gass Shack in Waco plans to "pivot around it and go heavy on the edibles." That's a practical response.
But edibles-only shops will be competing against a gray market that still sells higher-dose products without a license. And the profit margins on compliant 10mg gummies — with $5,000 in annual fees on top — are thin. Some shops will make it work. Many won't. Mark Bordas of the Texas Hemp Business Council estimates the rules affect over 8,000 registered retailers and an industry supporting 50,000 jobs.
Even if gummy vendors navigate March 31 successfully, there's a second deadline on the horizon that changes everything.
On November 12, 2025, President Trump signed H.R. 5371, which included Section 781 — a provision that caps all finished hemp consumer products at 0.4 milligrams of total intoxicating cannabinoids per container. Not per serving. Per container. It takes effect November 12, 2026.
To put that in perspective: a compliant Texas gummy contains 10mg of THC. The federal cap is 0.4mg. That's 25 times over the federal limit. A 5-pack of 10mg gummies? That's 50mg per container — 125 times the limit. The U.S. Hemp Roundtable estimates over 90% of all CBD products currently on the market — even non-intoxicating ones — exceed the 0.4mg threshold. Attorney Ashley Brandt described it as "less like a calibration and more like the rug being pulled out."
At 0.4mg per container, you're not really selling a THC product anymore. For comparison, that's less than what's naturally present in some hemp seed oils sold as food products. A standard dose of melatonin gummies has more psychoactive effect.
Here's the picture when you put both deadlines together:
March 31, 2026 — Texas DSHS Rules
• Smokable hemp/THCA flower: Banned
• Gummies (10–15mg max): Legal (by chemistry, not exemption)
• THC beverages: Legal
November 12, 2026 — Federal 0.4mg Cap
• Smokable hemp: Already banned in TX
• Gummies (10–15mg): Non-compliant (exceeds 0.4mg/container by 25x)
• THC beverages: Non-compliant
• 90%+ of CBD products: Non-compliant
Industry advocates view the 365-day implementation window as time to push Congress for alternative legislation. Whether that happens remains to be seen.
Texas banned recreational marijuana in 1931 — 95 years ago. The 2019 hemp loophole gave Texans their first legal alternative: products that were tested, taxed, and traceable.
Since then, hemp-derived THC has been sold in all 50 states for seven years with zero recorded overdose deaths. During that same period, alcohol killed approximately 665,000 Americans. Both numbers come from public health data. The product with zero deaths is the one being restricted. The product with 95,000 annual deaths remains on every grocery store shelf.
Retail licensing fees for hemp just went up 3,000%. For comparison, a Texas brewery license through TABC costs $3,000 biennially — meaning hemp retailers now pay more annually than alcohol producers.
These are just numbers. We think people deserve to see them side by side and draw their own conclusions.
The Texas Hemp Business Council is preparing a legal challenge and plans to seek an injunction. The Texas Supreme Court is separately reviewing whether DSHS has the authority to effectively reclassify hemp-derived cannabinoids through administrative rulemaking. Both cases could reshape the timeline. For now, March 31 stands.
March 15, 2026
Switchboard operators once connected every phone call in America. They were skilled, fast, essential. Then automatic switching came along and the job disappeared. Nobody called those careers pointless. The work mattered when it mattered. The world moved on, and so did the people who did it.
Travel agents, bank tellers, darkroom technicians, assembly line workers replaced by robotics — entire professions have been automated or made obsolete by better information, better tools, or simply better understanding. In every case, the people who did those jobs weren't failures. They were professionals doing their best with what was known at the time. But when the facts change, the process has to change too. That's not betrayal. That's how progress works.
So here's the question nobody in the DEA wants to hear: why can't you just admit you got it wrong?
Cannabis was placed on Schedule I in 1970. Richard Nixon did it against the explicit recommendation of his own commission — the Shafer Commission, which he personally appointed, which spent two years studying the issue and concluded cannabis should be decriminalized. He ignored them. The classification stuck. And for the next 55 years, an entire enforcement apparatus was built around a decision that was politically motivated from day one.
The agents who spent careers enforcing cannabis prohibition weren't villains. Most of them believed in the mission. They were told cannabis was dangerous, told it destroyed communities, told they were protecting the public. They made arrests, built cases, testified in court. They did the job as it was defined. And the work they did was real.
But since 2019, we can't unsee what we've seen. Seven years of legal hemp-derived THC sold in all 50 states with zero overdose deaths. State after state legalizing with no public health catastrophe. Peer-reviewed research showing CBD reversing liver disease, managing chronic pain better than opioids in elderly patients, and cannabinoids helping with multiple sclerosis. The FDA approving Epidiolex for seizures. The Supreme Court hearing arguments about whether cannabis users can own firearms. Half the country already has legal access.
The science has moved. The public has moved. Thirty-eight states have medical programs. Twenty-four have gone fully recreational. Gallup polls show 70% of Americans support legalization. The only thing that hasn't moved is Schedule I.
Admitting the classification was wrong doesn't erase anyone's career. It doesn't mean the work was meaningless. It means the information changed. The same way a doctor who prescribed thalidomide in the 1950s wasn't a bad doctor — they just didn't have the data yet. When the data arrived, medicine adapted. Nobody argued that updating the prescription guidelines was an insult to the physicians who wrote the old ones.
Processes evolve. That's not a weakness — it's the whole point of having processes in the first place. You measure, you learn, you adjust. A pilot doesn't keep flying toward a mountain because the original heading said to go that way. You update the course. The institution that can't update its own course isn't strong. It's stuck.
The pivot isn't the problem. Refusing to pivot is. Every day that cannabis stays Schedule I is a day the federal government is choosing to ignore its own data. It's a day that researchers face unnecessary barriers to studying a plant with documented medical applications. It's a day that veterans buying legal THC gummies in one state are federal criminals in another. It's a day the system is running on 1970 logic with 2026 evidence.
We're not asking anyone to feel ashamed. We're asking them to do the right thing. Read the data. Look at the seven-year track record. Acknowledge that a substance with zero overdose deaths in human history doesn't belong in the same category as heroin. The evidence is there. It's been there. We cannot unsee what we've seen since 2019.
Masters of one era become students of the next. That's not a tragedy. That's evolution. The only real failure is knowing the facts and choosing not to act on them.
March 15, 2026
In December 2018, the United States Congress passed the Farm Bill and accidentally launched the largest public safety experiment in modern drug policy history. By legalizing hemp and all its derivatives — including cannabinoids like delta-8 and delta-9 THC — the federal government gave the American public legal access to intoxicating cannabis products in all 50 states. No prescription. No dispensary. No state-by-state ballot initiative. Just legal THC, on shelves, coast to coast.
That was seven years ago. The beta test is over. The results are in.
Since 2019, the hemp-derived THC market has grown into a multi-billion dollar industry. Tens of millions of Americans have purchased legal THC gummies, beverages, tinctures, and vapes. Products are sold in gas stations, smoke shops, grocery stores, and online. They're shipped through the US mail. They're consumed by adults in every state, every county, every zip code. This is not a hypothetical — it happened. It's still happening. And here is the most important number from seven years of data: zero overdose deaths from hemp-derived THC. Zero.
Not one. Not from delta-8. Not from delta-9. Not from THC-O, THC-P, HHC, or any other cannabinoid sold under the Farm Bill. In seven years of nationwide, unregulated, over-the-counter access, the death toll from hemp-derived THC is identical to the death toll from cannabis in general: zero. The CDC has not recorded it. The DEA has not documented it. No coroner's report in any state has listed hemp-derived THC as a cause of death.
For context, during those same seven years: alcohol killed approximately 665,000 Americans (95,000 per year). Tobacco killed roughly 3.36 million (480,000 per year). Opioids killed over 500,000. Even acetaminophen — Tylenol — caused an estimated 3,500 deaths. All of those products remain legal, regulated, and sold freely. The product with zero deaths is the one being banned.
Think about what this data means. Congress gave the country seven years of legal, publicly accessible THC. It wasn't tightly controlled. It wasn't limited to dispensaries with medical cards. It was as available as energy drinks. And after seven years, the public health catastrophe that prohibitionists have warned about for decades simply did not happen. No wave of overdose deaths. No spike in fatal car crashes attributable to THC. No emergency room crisis. The data exists. It has been collected. It tells a very clear story.
This is the part that matters for policy: the beta test answered the question. The question was never "is THC perfectly harmless?" — no substance is. The question was "does legal THC access create a public safety emergency?" Seven years of data say no. Not even close. The logical policy response to this data is straightforward: regulate THC like alcohol. Age-gate it. Label it. Tax it. Test it for contaminants. Let adults buy it legally and keep it away from minors — just like beer, wine, and spirits.
The vessel doesn't matter. Hemp-derived THC, marijuana-derived THC, delta-8, delta-9 — the molecule is the molecule. Whether the THC comes from a hemp plant or a marijuana plant, the safety profile is the same. Cannabis, in all its forms, under all its names, through every delivery method, across seven years of public access: zero deaths. That is not an opinion. That is a dataset.
Banning a product with a seven-year track record of zero deaths while alcohol — a product responsible for 95,000 deaths per year — remains available at every gas station in America is not a policy based on evidence. It is a policy based on something else. Campaign contributions, industry lobbying, and political convenience are all documented in public records. The numbers are there for anyone willing to look.
The 2018 Farm Bill gave the country a seven-year beta test. The data is conclusive. THC — from any plant, in any form — does not kill people. That's not a talking point. That's the result. The only question left is whether lawmakers will follow the evidence or continue following the money.
March 10, 2026
On March 31, 2026, Texas will ban all intoxicating hemp-derived cannabis products. Governor Abbott's Executive Order GA-56, enforced through DSHS administrative rulemaking, will shut down an estimated 9,100 retail locations and eliminate access to legal THC for millions of Texans. Among them: veterans who use hemp-derived THC products to manage PTSD, chronic pain, traumatic brain injuries, and service-related anxiety.
Texas has one of the most restrictive medical cannabis programs in the country. The Compassionate Use Program covers only a handful of conditions and limits THC content so severely that many patients report the products are ineffective. For thousands of Texas veterans, hemp-derived delta-8 and delta-9 THC products — sold legally since the 2018 Farm Bill — became a lifeline. Legal, accessible, affordable, and they work. No prescription needed. No VA waitlist. No judgment.
When people lose access to regulated products that manage real medical conditions, the need for relief doesn't go away. History shows they seek alternatives. In 2026, the unregulated market includes fentanyl-laced products, counterfeit pills, and THC cartridges with unknown chemicals. A veteran currently managing PTSD symptoms with a legal 25mg gummy will still need relief after March 31 — and the available options outside the legal market carry serious risks.
According to public campaign finance records, Texas lawmakers who backed the hemp ban received over $250,000 from the alcohol industry, including $50,000 from the Beer Alliance of Texas PAC. The stated goal of the hemp ban is to protect children. Alcohol is responsible for approximately 95,000 American deaths per year, including an estimated 3,500 involving minors. The product being banned — hemp-derived cannabis — has zero recorded overdose deaths. Zero. Those two numbers, side by side, are worth sitting with.
DSHS published the new hemp rules on December 26 — the day after Christmas — giving the industry limited time to respond. Retail licensing fees increased from $150 to $5,000 per year (a 33x increase). Manufacturing fees went from $250 to $10,000 (40x). The .3% total THC per serving cap makes virtually every effective product non-compliant. A 5mg gummy — roughly equivalent to half a light beer in intoxication — would no longer be legal. The proposed federal limit of 0.4mg THC per entire container (not per serving) would go even further. Whether this amounts to regulation or effective prohibition is a question worth considering.
Texas has 1.7 million veterans. When the ban takes effect, those who currently rely on legal hemp products for relief will need to find alternatives. The question is worth asking: should a product with zero recorded deaths be banned while products responsible for 95,000 deaths per year remain legal and actively promoted? We believe Texans deserve to see the facts and decide for themselves.
March 3, 2026
Alcohol kills approximately 95,000 Americans every year. Tobacco kills 480,000. Opioids killed over 80,000 in 2023 alone. Cannabis? Zero recorded overdose deaths. Ever. In the entire history of human use. The substance that remains federally illegal has a death toll of zero, while substances sold at every corner store and prescribed by doctors account for hundreds of thousands of deaths annually.
The CDC, the DEA, and the WHO have all failed to document a single confirmed case of a fatal cannabis overdose. The lethal dose of THC is estimated to be so astronomically high that a human would need to consume roughly 1,500 pounds in 15 minutes to reach it — a physical impossibility. Meanwhile, acetaminophen (the stuff in Tylenol) kills about 500 Americans per year through accidental overdose.
So why is cannabis still Schedule I — classified alongside heroin as having "no accepted medical use" and "high potential for abuse"? The alcohol industry, pharmaceutical companies, and private prison operators have spent significant amounts on lobbying and campaign contributions to legislators who oppose legalization. When legalization threatens market share, the incentive to maintain the status quo is clear.
Zero deaths. That's the number. When legislators vote against legalization while accepting donations from alcohol and pharmaceutical PACs, the public record is worth examining. We present the facts and let you decide.
March 3, 2026
When a politician stands at a podium and tells you cannabis is dangerous, the first question you should ask is: who's paying for that podium? The alcohol industry spent over $30 million on federal lobbying in 2023. The pharmaceutical industry spent $374 million. And a significant chunk of that money flows directly to politicians who vote against cannabis legalization.
The Beer, Wine & Spirits PAC, the National Beer Wholesalers Association, and Anheuser-Busch InBev are among the largest donors to anti-cannabis legislators. They know that legal cannabis cuts into alcohol sales — studies show that states with legal cannabis see a measurable decline in alcohol consumption. So they fund the opposition. Not because cannabis is dangerous, but because it threatens their market share.
Big Pharma plays the same game. Cannabis competes with opioids for pain management, with benzodiazepines for anxiety, and with sleep medications for insomnia. A plant you can grow in your backyard is a direct threat to drugs that cost hundreds of dollars per prescription. So they fund anti-cannabis research, lobby against legalization, and push for regulations that make it harder for cannabis businesses to compete.
The pattern is consistent. Companies whose products are responsible for hundreds of thousands of American deaths every year are funding politicians who say cannabis — with its zero-death track record — is too dangerous to legalize. We document the campaign contributions. We present the public records. That's what the Double Standard Watch is for — putting the facts side by side so you can see the full picture.
March 4, 2026
Hemp is one of the most versatile plants on Earth. It can be used to make textiles, paper, biodegradable plastics, construction materials, biofuel, animal feed, and hundreds of other products. It grows fast, requires minimal pesticides, and actually improves soil health. Henry Ford built a car panel from hemp. The US Constitution was drafted on hemp paper. And for most of human history, it was one of the most widely cultivated crops on the planet.
Then came the 2018 Farm Bill, which legalized hemp at the federal level. The industry exploded — farmers planted thousands of acres, processors built new facilities, and consumers gained access to CBD products, hemp-derived delta-8 THC, and a growing range of cannabinoid products. But now the incumbents are fighting back. Proposed regulations in the 2024 and 2025 Farm Bill revisions threaten to gut the hemp industry by banning naturally occurring cannabinoids and imposing restrictions that would make most hemp products illegal overnight.
Which industries stand to lose from hemp's growth? Cotton, timber, petroleum-based plastics, and pharmaceutical companies all compete with hemp products. A sustainable, renewable crop that can replace petroleum products, reduce deforestation, and provide affordable medicine represents a significant competitive challenge to established industries.
We're watching every regulatory move, every farm bill amendment, and every lobbying dollar aimed at stopping the hemp revolution. The plant has been here for thousands of years. It's not going anywhere.
March 5, 2026
For decades, the federal government made it nearly impossible to study cannabis. Schedule I classification meant researchers needed DEA approval, could only use government-grown cannabis (notoriously low quality), and faced career-limiting stigma. The result was a significant knowledge gap. But that's changing fast.
Peer-reviewed studies are now showing what patients have known for years. A 2023 meta-analysis in the Journal of the American Medical Association found that medical cannabis significantly reduces chronic pain with fewer side effects than opioids. Clinical trials at institutions like Johns Hopkins, UCLA, and the University of Colorado are documenting cannabis efficacy for PTSD, epilepsy, chemotherapy-induced nausea, multiple sclerosis spasticity, and anxiety disorders.
The endocannabinoid system — the body's own network of cannabinoid receptors — is one of the most important signaling systems in human biology. CB1 and CB2 receptors regulate pain, mood, appetite, immune response, and neuroplasticity. The science isn't just supportive of cannabis — it suggests we evolved alongside it.
We track every major study, every clinical trial result, and every breakthrough in cannabinoid science. The evidence continues to build, and we believe it deserves wider attention.
March 5, 2026
The numbers tell the story. As of 2026, 24 states plus Washington DC have legalized recreational cannabis. 38 states have medical cannabis programs. Over 70% of Americans support federal legalization — a number that has nearly doubled in just 15 years. Public opinion has shifted significantly.
Internationally, the dominoes are falling even faster. Germany legalized recreational cannabis in 2024, becoming the largest European market overnight. Thailand legalized in 2022 (though they're now reconsidering restrictions). Canada has been fully legal since 2018 and the sky hasn't fallen — tax revenue is up, impaired driving is flat, and youth use rates haven't increased.
The economic case is undeniable. Legal cannabis generated over $30 billion in US sales in 2023 and created over 400,000 direct jobs. Tax revenue from cannabis is funding schools, roads, and public health programs in states across the country. Colorado alone has collected over $2 billion in cannabis tax revenue since legalization.
Every state that legalizes adds to the data. Studies consistently show no significant increase in youth use, no spike in traffic fatalities, and no collapse of public health in legal markets. The evidence from real-world implementation continues to grow. We're here to document it.
March 6, 2026
In 1970, Richard Nixon signed the Controlled Substances Act. His domestic policy advisor John Ehrlichman later described the political motivations in a 1994 interview published by Harper's Magazine: "We knew we couldn't make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities." This is a direct quote from the architect of the policy, published in a major American magazine.
Cannabis was placed in Schedule I — the most restrictive category, reserved for substances with "no accepted medical use" and "high potential for abuse." This was done against the explicit recommendation of the Shafer Commission, which Nixon himself appointed. The commission spent two years studying cannabis and concluded in 1972 that it should be decriminalized. The recommendation was not adopted.
The Drug Enforcement Administration was created in 1973 — one year after the Shafer Commission was ignored. Today the DEA has a budget of over $3.4 billion. Cannabis arrests account for more drug arrests than any other substance. The financial relationship between prohibition enforcement and agency funding is worth noting.
The growth of for-profit prisons added another dimension. Companies like CoreCivic (formerly Corrections Corporation of America) and GEO Group generate billions in revenue from incarceration. Cannabis convictions have been a significant source of that pipeline. The US incarcerates more people per capita than any country on Earth. Some of these companies have lobbied against legalization and contributed to politicians who support prohibition. The financial incentives are worth examining.
The enforcement disparities are documented. According to the ACLU, Black Americans are arrested for cannabis at 3.73 times the rate of white Americans, despite similar usage rates. In some counties, that ratio reaches 10 to 1. These numbers raise important questions about whether Schedule I classification reflects scientific evidence — or something else entirely.
A plant with zero overdose deaths, documented medical applications, and majority public support for legalization remains in the same legal category as heroin. The question worth asking: does the Schedule I classification reflect current science, or does it reflect a policy decision made in 1970 that has never been meaningfully revisited?
March 7, 2026
Here are the annual death toll numbers in the United States, from public health data: Alcohol: approximately 95,000 deaths (liver disease, poisoning, drunk driving, violence, and cancers). Tobacco: 480,000. Prescription opioids: over 16,000. Even over-the-counter acetaminophen (Tylenol) causes about 500 deaths per year from accidental overdose. Cannabis: zero confirmed fatal overdoses in recorded medical history.
Alcohol is the third leading preventable cause of death in America, linked to over 200 disease and injury conditions. Alcohol withdrawal can be fatal — delirium tremens has a mortality rate of up to 37% without treatment. Cannabis withdrawal symptoms are generally limited to irritability and difficulty sleeping. The medical profiles of these two substances are quite different.
Child safety is often cited as a reason for cannabis restrictions. Here is what public health data shows about children and alcohol: Alcohol is the #1 drug involved in teen deaths. Approximately 3,500 people under 21 die from alcohol-related causes every year in the US. An additional 119,000 emergency room visits by people aged 12-21 are alcohol-related annually. Underage drinking is a factor in nearly half of all teen car crash fatalities. Alcohol is available at gas stations, grocery stores, and restaurants nationwide. When child safety is the stated justification for cannabis policy, these numbers provide important context.
Prescription drugs are also worth examining. Benzodiazepines (Xanax, Valium, Klonopin) were involved in over 12,000 overdose deaths in 2022. These are drugs prescribed by doctors, manufactured by pharmaceutical companies, and marketed directly to consumers. Cannabis has been used to treat some of the same conditions — anxiety, insomnia, chronic pain — without the lethal overdose risk. The pharmaceutical industry has a financial interest in which treatment options are available to patients. That relationship is worth understanding.
When evaluating cannabis policy, one question provides useful clarity: how many people did it kill last year? Then compare that number to alcohol, opioids, tobacco, and even Tylenol. The numbers speak for themselves — and they are all a matter of public record.
Built with Python · Powered by AI Agents